The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Small intestinal bacterial overgrowth as a cause for irritable bowel syndrome: guilty or not guilty?
Abstract
PURPOSE OF REVIEW: Small intestinal bacterial overgrowth (SIBO) has been proposed as a cause of irritable bowel syndrome (IBS). However, this relationship has been subject to controversy. This review aims to provide a current perspective on the SIBO-IBS hypothesis. RECENT FINDINGS: Case-control studies evaluating the prevalence of SIBO in IBS and healthy individuals have shown conflicting results. Moreover, the tests available in routine clinical practice to diagnose SIBO are not valid and lack both sensitivity and specificity. Hence, interpreting the effect of interventions based on these tests is fraught with uncertainty. Furthermore, the SIBO-IBS hypothesis has paved the way to assess antibiotic therapy in nonconstipated IBS, with rifaximin, a nonabsorbable antibiotic, showing modest but significant clinical benefit. However, individuals were not tested for SIBO and the mechanism of action of rifaximin in IBS remains to be elucidated. Preliminary data suggest that rifaximin decreases microbial richness and previous studies have noted antibacterial interventions in IBS to reduce colonic fermentation and improve symptoms. The advent of rapid culture-independent molecular techniques is a promising tool that will seek to clarify and advance our understanding of the gut microbial function. SUMMARY: The SIBO-IBS hypothesis lacks convincing evidence but remains under scrutiny. The mechanism resulting in symptom improvement after rifaximin treatment in some IBS individuals requires exploration. Novel molecular techniques provide an exciting and challenging opportunity to explore the host-gut microbiota interaction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“SIBO has been proposed to trigger symptoms in FD142, although studies examining the role of SIBO in FD are limited by the relative inaccessibility of the more distal regions of the small intestine and concerns regarding accuracy and interpretation of available testing methods for the diagnosis of SIBO143.”
From The gut Microbiome in adult and pediatric functional gastrointestinal disorders (2019) · cites this paper as [143]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036
Enck, P., Aziz, Q., Barbara, G., Farmer, A. D., Fukudo, S., Mayer, E. A., Niesler, B., Quigley, E. M. M., Rajilić-Stojanović, M., Schemann, M., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.14 · Cited by 997
Self-citationIntestinal microbiota in functional bowel disorders: a Rome foundation report
Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M. R., Spiller, R. C., Vanner, S., Verdu, E. F., Whorwell, P. J., & Zoetendal, E. G. (2013) · Gut · doi:10.1136/gutjnl-2012-302167 · Cited by 939
Self-citationEradication of Small Intestinal Bacterial Overgrowth Reduces Symptoms of Irritable Bowel Syndrome
Pimentel, M., Chow, E. J., & Lin, H. C. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.03368.x · Cited by 780
Pimentel, M. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)05902-6 · Cited by 669
Small intestinal bacterial overgrowth in patients with irritable bowel syndrome
Posserud, I., Stotzer, P.-O., Björnsson, E. S., Abrahamsson, H., & Simrén, M. (2007) · Gut · doi:10.1136/gut.2006.108712 · Cited by 499
Self-citationAbnormal colonic fermentation in irritable bowel syndrome
King, T., Elia, M., & Hunter, J. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02146-1 · Cited by 473
(2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.03951.x · Cited by 444
Use and abuse of hydrogen breath tests
Simrén, M., & Stotzer, P.-O. (2006) · Gut · doi:10.1136/gut.2005.075127 · Cited by 418
Self-citationSmall Intestinal Bacterial Overgrowth: A Framework for Understanding Irritable Bowel Syndrome
Lin, H. C. (2004) · JAMA · doi:10.1001/jama.292.7.852 · Cited by 396
Cited by
Diagnosis and Treatment of Irritable Bowel Syndrome: A Review
Camilleri, M. (2021) · JAMA · doi:10.1001/jama.2020.22532 · Cited by 362
The gut Microbiome in adult and pediatric functional gastrointestinal disorders
Shin, A., Preidis, G. A., Shulman, R., & Kashyap, P. C. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.08.054 · Cited by 163
“SIBO has been proposed to trigger symptoms in FD,(142) although studies examining the role of SIBO in FD are limited by the relative inaccessibility of the more distal regions of the small intestine and concerns regarding the accuracy and interpretation of available testing methods for the diagnosis of SIBO.(143) Rece…”
Probiotics, Nutrition, and the Small Intestine
Judkins, T. C., Archer, D. L., Kramer, D. C., & Solch-Ottaiano, R. J. (2020) · Current Gastroenterology Reports · doi:10.1007/s11894-019-0740-3 · Cited by 141
The overlap between irritable bowel syndrome and organic gastrointestinal diseases
Aziz, I., & Simrén, M. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30212-0 · Cited by 134
Self-citationThe Spectrum of Small Intestinal Bacterial Overgrowth (SIBO)
Quigley, E. M. M. (2019) · Current Gastroenterology Reports · doi:10.1007/s11894-019-0671-z · Cited by 117
Metadata
- Authors
- Aziz, I., Törnblom, H., & Simrén, M.
- Affiliations
- University of Gothenburg (SE)
- Corresponding author
- Simrén, Magnus
- Venue
- Current Opinion in Gastroenterology
- Published
- 2017-05
- Volume
- 33
- Issue
- 3
- Pages
- 196-202
- ISSN
- 0267-1379 (ISSN-L)
- OpenAlex
- W2594592046
- Cited by
- 45
- References
- 48
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 4 · 2023: 4 · 2022: 8 · 2021: 5 · 2020: 5 · 2019: 8 · 2018: 6 · 2017: 3
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- Funders
- Vetenskapsrådet
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
- Keywords
- small intestinal bacterial overgrowth, irritable bowel syndrome, SIBO diagnosis, SIBO prevalence, rifaximin, non-absorbable antibiotics, gut microbiota, colonic fermentation
- MeSH terms
- Gastrointestinal Microbiome, Rifaximin, Anti-Infective Agents, Blind Loop Syndrome, Breath Tests, Humans, Intestine, Small, Rifamycins, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Small intestinal bacterial overgrowth as a cause for irritable bowel syndrome: guilty or not guilty? https://app.cochat.ai/papers/10.1097/mog.0000000000000348
- The paper
- Aziz, I., Törnblom, H., & Simrén, M. (2017). Small intestinal bacterial overgrowth as a cause for irritable bowel syndrome: guilty or not guilty? Current Opinion in Gastroenterology. https://doi.org/10.1097/mog.0000000000000348
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.